Advanced Optics Electronics Buys 21% of Disease Management Co.; Biomoda Moves Into ASR Sales Targeted at European Markets.Business Editors/Health/Medical Writers ALBUQUERQUE, N.M.--(BUSINESS WIRE)--Feb. 19, 2004 Advanced Optics Electronics, Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :ADOT ADOT Arizona Department Of Transportation ADOT Alaska Department of Transportation ADOT Fédération des Associations pour le Don d'Organes et de Tissus Humains ADOT Active Duty Other Than Training ADOT Automatic Digital Optical Tracker ADOT Advanced Display Optimization Tools ) has completed the acquisition of approximately 21% of Genomed, Inc., a St. Louis-based publicly traded biotech company. Genomed, Inc. is a Next Generation Disease Management TM company identifying the molecular pathways that cause disease. Genomed has filed more than 30 provisional patents and is now focusing its resources to advancing many of these patents to the next level. Biomoda, Inc., 30% held directly and indirectly by ADOT, is proceeding with the raising of capital on its SB-2 registration filed and approved by the SEC. Biomoda, Inc. has commenced development of an ASR (Automatic Speech Recognition) Using voice recognition to replace keypad entry for telephone voice menus. Typically used to speak the digits 0 through 9 insted of keying them, ASR systems may be able to recognize a limited vocabulary. See voice recognition and AVSR. (Analyte Specific Reagent The FDA defines analyte specific reagents (ASRs) in 21 CFR 864.4020 as “antibodies, both polyclonal and monoclonal, specific receptor proteins, ligands, nucleic acid sequences, and similar reagents which, through specific binding or chemical reaction with ) approval level product. This is an approval route available in leading countries of Europe. Biomoda's ASR sales are estimated to approximate Biomoda bulk sales and is scheduled to move forward rapidly. Biomoda, Inc.'s securities placement program is targeted to be completed very soon. ADOT's "COLOR-CHEK" development is moving along smoothly with the appointment of an Indiana-based firm to handle cosmetic packaging for this unit. The company anticipates a very competitive sales price in the area of $49.95 per unit. ADOT's 10K is set to be filed on or before March 27th and is expected to reflect a substantially improved financial condition over the same period last year. Advanced Optics Electronics, Inc. (OTCBB:ADOT) is a technology company based in Albuquerque, New Mexico “Albuquerque” redirects here. For other uses, see Albuquerque (disambiguation). Albuquerque (pronounced [ˈæl.bə.kɚ.kiː], Spanish: [al.βu. . The company maintains an R&D facility and manufacturing plant, and is engaged in building large-scale flat panel displays A thin display screen for computer and TV usage. The first flat panels appeared on laptop computers in the mid-1980s, and the LCD technology became the standard. Stand-alone LCD screens became available for desktop computers in the mid-1990s and exceeded sales of CRTs for the first time utilizing its patented and patent pending technology. In addition to the core business of ADOT, the company has made a strategic technology oriented investment in BIOMODA, Inc. BIOMODA, Inc. is a company that holds patents and patents pending domestically and internationally for the early detection of Lung Cancer lung cancer, cancer that originates in the tissues of the lungs. Lung cancer is the leading cause of cancer death in the United States in both men and women. Like other cancers, lung cancer occurs after repeated insults to the genetic material of the cell. . ADOT currently holds directly and indirectly 30% of BIOMODA, Inc. This news release contains forward-looking statements that involve a high degree of risk and uncertainty. Such statements include, but are not limited to, statements containing the words "believes," "anticipates," "expects," "estimates," and words of similar import. The Company's actual results could differ materially from any forward-looking statements, which reflect management's opinions only as of the date of this report, as a result of risks and uncertainties that exist in our operation, development efforts and business environment. The Company undertakes no obligation to revise or publicly release the results of any revisions to these forward-looking statements. You should carefully review the risk factors in other documents that the Company files from time to time with the Securities and Exchange Commission, including its Quarterly Reports on Form 10-Q Form 10-Q See 10-Q. . |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion